SNDX — Syndax Pharmaceuticals Share News
0.000.00%
Last trade - 00:00- $1.22bn
- $1.25bn
- $172.35m
Syndax says mid-stage trial of lung disease treatment fails main goal, ends development
Syndax Pharmaceuticals Inc reports results for the quarter ended June 30 - Earnings Summary
Syndax Q2 revenue jumps 92% on Revuforj, Niktimvo demand
Brief: Syndax Pharmaceuticals Q2 Operating Income USD -39.995 Million
Brief: Syndax Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
U.S. STOCKS ON THE MOVE -Honeywell, Broadcom, Carlyle
U.S. STOCKS ON THE MOVE-UnitedHealth, Pinterest, Celcuity
Syndax Pharma slides after $250 mln convertible bond sale
Brief: Syndax Announces Private Placement Of $250.0 Million Of Convertible Senior Notes
Syndax Q1 revenue jumps on cancer drug sales
U.S. RESEARCH ROUNDUP-Dow, Oracle, Shopify
Brief: Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Syndax Q4 revenue rises 38%, net income misses estimates
Brief: Syndax Pharmaceuticals Q4 Operating Expenses USD 131.276 Million
Brief: Syndax Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule
Syndax Pharmaceuticals Q3 revenue misses estimates
Brief: Syndax Pharmaceuticals Q3 EPS USD -0.7 Vs. IBES Estimate USD -0.72
Brief: FDA Approves Revumenib For Relapsed Or Refractory Acute Myeloid Leukemia With A Susceptible NPM1 Mutation
Syndax Pharma rises after H.C. Wainwright starts coverage with 'buy'